Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy
Background We previously introduced a classification system for patients with localized pancreatic adenocarcinoma that integrates assessments of tumor anatomy, cancer biology, and patient physiology. By means of this system, we sought to analyze outcomes of patients with resectable anatomy but heter...
Gespeichert in:
| Veröffentlicht in: | Annals of surgical oncology 2012-06, Vol.19 (6), p.2045-2053 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2053 |
|---|---|
| container_issue | 6 |
| container_start_page | 2045 |
| container_title | Annals of surgical oncology |
| container_volume | 19 |
| creator | Tzeng, Ching-Wei D. Fleming, Jason B. Lee, Jeffrey E. Xiao, Lianchun Pisters, Peter W. T. Vauthey, Jean-Nicolas Abdalla, Eddie K. Wolff, Robert A. Varadhachary, Gauri R. Fogelman, David R. Crane, Christopher H. Balachandran, Aparna Katz, Matthew H. G. |
| description | Background
We previously introduced a classification system for patients with localized pancreatic adenocarcinoma that integrates assessments of tumor anatomy, cancer biology, and patient physiology. By means of this system, we sought to analyze outcomes of patients with resectable anatomy but heterogeneous biology and physiology who were treated with neoadjuvant therapy.
Methods
We evaluated consecutive patients (2002–2007) with anatomically potentially resectable cancers treated with chemotherapy or chemoradiation before potential pancreatectomy. We compared clinical factors and outcomes of patients classified as having disease that was clinically resectable (CR; no extrapancreatic disease, preserved performance status); suspicion for extrapancreatic disease (BR-B); or marginal performance status or significant comorbidity (BR-C). Patients with borderline resectable anatomy (BR-A) were excluded.
Results
Resection rates for 138 CR, 41 BR-B, and 38 BR-C patients were 75, 46, and 37%, respectively (
P
|
| doi_str_mv | 10.1245/s10434-011-2211-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1015012084</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2666003591</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-9d33414a909f00e27e232760bbf02d4d404803bf73ccd914366651609b738fc83</originalsourceid><addsrcrecordid>eNp1kc1u1TAQhSNERUvhAdggS6wD4584yTK6lB-pahG6rCPHGVNfJfbFdkD3bXjUOkqL2HQzczTzzZnFKYo3FN5TJqoPkYLgogRKS8ZyEc-KC1rliZANfZ41yKZsmazOi5cxHgBozaF6UZwzxqqmofKi-PsRjXU4kt1kndVqykLFaE3WyXoXSReQdDF6bVXK3B-b7sjtkrSfkXhDvmUMXYrbonMq-Xn1mU7kO0bUSQ0TZsrpgBnVpBvRea2Cts7PiuzX8aPvDXo1HpbfyiWyv8OgjqdXxZlRU8TXD_2y-PHpar_7Ul7ffv66665LzWuWynbkXFChWmgNALIaGWe1hGEwwEYxChAN8MHUXOuxpYJLKSsqoR1q3hjd8Mvi3eZ7DP7XgjH1B78El1_2FGgFlEEjMkU3SgcfY0DTH4OdVThlqF8z6bdM-pxJv2bSrzdvH5yXYcbx38VjCBlgGxDzyv3E8P_rp1zvAU1wmKQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1015012084</pqid></control><display><type>article</type><title>Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Tzeng, Ching-Wei D. ; Fleming, Jason B. ; Lee, Jeffrey E. ; Xiao, Lianchun ; Pisters, Peter W. T. ; Vauthey, Jean-Nicolas ; Abdalla, Eddie K. ; Wolff, Robert A. ; Varadhachary, Gauri R. ; Fogelman, David R. ; Crane, Christopher H. ; Balachandran, Aparna ; Katz, Matthew H. G.</creator><creatorcontrib>Tzeng, Ching-Wei D. ; Fleming, Jason B. ; Lee, Jeffrey E. ; Xiao, Lianchun ; Pisters, Peter W. T. ; Vauthey, Jean-Nicolas ; Abdalla, Eddie K. ; Wolff, Robert A. ; Varadhachary, Gauri R. ; Fogelman, David R. ; Crane, Christopher H. ; Balachandran, Aparna ; Katz, Matthew H. G.</creatorcontrib><description>Background
We previously introduced a classification system for patients with localized pancreatic adenocarcinoma that integrates assessments of tumor anatomy, cancer biology, and patient physiology. By means of this system, we sought to analyze outcomes of patients with resectable anatomy but heterogeneous biology and physiology who were treated with neoadjuvant therapy.
Methods
We evaluated consecutive patients (2002–2007) with anatomically potentially resectable cancers treated with chemotherapy or chemoradiation before potential pancreatectomy. We compared clinical factors and outcomes of patients classified as having disease that was clinically resectable (CR; no extrapancreatic disease, preserved performance status); suspicion for extrapancreatic disease (BR-B); or marginal performance status or significant comorbidity (BR-C). Patients with borderline resectable anatomy (BR-A) were excluded.
Results
Resection rates for 138 CR, 41 BR-B, and 38 BR-C patients were 75, 46, and 37%, respectively (
P
< 0.001). Metastases, detected during treatment in 23% of patients, were the most common contraindication to resection among CR (15%) and BR-B (46%) patients. Performance status rarely precluded surgery except among BR-C (32%) patients. Factors associated with selection against surgery were older age, poor performance status, pain, and therapeutic complications (
P
< 0.05). The median overall survival of all patients was 21 months. Resected and unresected BR-B and BR-C patients had median overall survival durations similar to those of resected and unresected CR patients, respectively (
P
> 0.22).
Conclusions
This system describes discrete clinical subgroups of patients with pancreatic cancer who have similar, potentially resectable tumor anatomy but heterogeneous physiology and cancer biology. It may be used with neoadjuvant therapy to predict outcomes, individualize treatment algorithms, and optimize survival.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1245/s10434-011-2211-4</identifier><identifier>PMID: 22258816</identifier><language>eng</language><publisher>New York: Springer-Verlag</publisher><subject>Adenocarcinoma - mortality ; Adenocarcinoma - pathology ; Adenocarcinoma - therapy ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carcinoma, Pancreatic Ductal - mortality ; Carcinoma, Pancreatic Ductal - pathology ; Carcinoma, Pancreatic Ductal - therapy ; Cisplatin - administration & dosage ; Combined Modality Therapy ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; Female ; Follow-Up Studies ; Gemcitabine ; Humans ; Male ; Medicine ; Medicine & Public Health ; Neoadjuvant Therapy - mortality ; Neoplasm Staging ; Oncology ; Pancreatectomy - mortality ; Pancreatic Neoplasms - mortality ; Pancreatic Neoplasms - pathology ; Pancreatic Neoplasms - therapy ; Pancreatic Tumors ; Prognosis ; Retrospective Studies ; Surgery ; Surgical Oncology ; Survival Rate</subject><ispartof>Annals of surgical oncology, 2012-06, Vol.19 (6), p.2045-2053</ispartof><rights>Society of Surgical Oncology 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-9d33414a909f00e27e232760bbf02d4d404803bf73ccd914366651609b738fc83</citedby><cites>FETCH-LOGICAL-c372t-9d33414a909f00e27e232760bbf02d4d404803bf73ccd914366651609b738fc83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1245/s10434-011-2211-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1245/s10434-011-2211-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22258816$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tzeng, Ching-Wei D.</creatorcontrib><creatorcontrib>Fleming, Jason B.</creatorcontrib><creatorcontrib>Lee, Jeffrey E.</creatorcontrib><creatorcontrib>Xiao, Lianchun</creatorcontrib><creatorcontrib>Pisters, Peter W. T.</creatorcontrib><creatorcontrib>Vauthey, Jean-Nicolas</creatorcontrib><creatorcontrib>Abdalla, Eddie K.</creatorcontrib><creatorcontrib>Wolff, Robert A.</creatorcontrib><creatorcontrib>Varadhachary, Gauri R.</creatorcontrib><creatorcontrib>Fogelman, David R.</creatorcontrib><creatorcontrib>Crane, Christopher H.</creatorcontrib><creatorcontrib>Balachandran, Aparna</creatorcontrib><creatorcontrib>Katz, Matthew H. G.</creatorcontrib><title>Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><addtitle>Ann Surg Oncol</addtitle><description>Background
We previously introduced a classification system for patients with localized pancreatic adenocarcinoma that integrates assessments of tumor anatomy, cancer biology, and patient physiology. By means of this system, we sought to analyze outcomes of patients with resectable anatomy but heterogeneous biology and physiology who were treated with neoadjuvant therapy.
Methods
We evaluated consecutive patients (2002–2007) with anatomically potentially resectable cancers treated with chemotherapy or chemoradiation before potential pancreatectomy. We compared clinical factors and outcomes of patients classified as having disease that was clinically resectable (CR; no extrapancreatic disease, preserved performance status); suspicion for extrapancreatic disease (BR-B); or marginal performance status or significant comorbidity (BR-C). Patients with borderline resectable anatomy (BR-A) were excluded.
Results
Resection rates for 138 CR, 41 BR-B, and 38 BR-C patients were 75, 46, and 37%, respectively (
P
< 0.001). Metastases, detected during treatment in 23% of patients, were the most common contraindication to resection among CR (15%) and BR-B (46%) patients. Performance status rarely precluded surgery except among BR-C (32%) patients. Factors associated with selection against surgery were older age, poor performance status, pain, and therapeutic complications (
P
< 0.05). The median overall survival of all patients was 21 months. Resected and unresected BR-B and BR-C patients had median overall survival durations similar to those of resected and unresected CR patients, respectively (
P
> 0.22).
Conclusions
This system describes discrete clinical subgroups of patients with pancreatic cancer who have similar, potentially resectable tumor anatomy but heterogeneous physiology and cancer biology. It may be used with neoadjuvant therapy to predict outcomes, individualize treatment algorithms, and optimize survival.</description><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - therapy</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carcinoma, Pancreatic Ductal - mortality</subject><subject>Carcinoma, Pancreatic Ductal - pathology</subject><subject>Carcinoma, Pancreatic Ductal - therapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Combined Modality Therapy</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gemcitabine</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoadjuvant Therapy - mortality</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Pancreatectomy - mortality</subject><subject>Pancreatic Neoplasms - mortality</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Pancreatic Neoplasms - therapy</subject><subject>Pancreatic Tumors</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Survival Rate</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kc1u1TAQhSNERUvhAdggS6wD4584yTK6lB-pahG6rCPHGVNfJfbFdkD3bXjUOkqL2HQzczTzzZnFKYo3FN5TJqoPkYLgogRKS8ZyEc-KC1rliZANfZ41yKZsmazOi5cxHgBozaF6UZwzxqqmofKi-PsRjXU4kt1kndVqykLFaE3WyXoXSReQdDF6bVXK3B-b7sjtkrSfkXhDvmUMXYrbonMq-Xn1mU7kO0bUSQ0TZsrpgBnVpBvRea2Cts7PiuzX8aPvDXo1HpbfyiWyv8OgjqdXxZlRU8TXD_2y-PHpar_7Ul7ffv66665LzWuWynbkXFChWmgNALIaGWe1hGEwwEYxChAN8MHUXOuxpYJLKSsqoR1q3hjd8Mvi3eZ7DP7XgjH1B78El1_2FGgFlEEjMkU3SgcfY0DTH4OdVThlqF8z6bdM-pxJv2bSrzdvH5yXYcbx38VjCBlgGxDzyv3E8P_rp1zvAU1wmKQ</recordid><startdate>20120601</startdate><enddate>20120601</enddate><creator>Tzeng, Ching-Wei D.</creator><creator>Fleming, Jason B.</creator><creator>Lee, Jeffrey E.</creator><creator>Xiao, Lianchun</creator><creator>Pisters, Peter W. T.</creator><creator>Vauthey, Jean-Nicolas</creator><creator>Abdalla, Eddie K.</creator><creator>Wolff, Robert A.</creator><creator>Varadhachary, Gauri R.</creator><creator>Fogelman, David R.</creator><creator>Crane, Christopher H.</creator><creator>Balachandran, Aparna</creator><creator>Katz, Matthew H. G.</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20120601</creationdate><title>Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy</title><author>Tzeng, Ching-Wei D. ; Fleming, Jason B. ; Lee, Jeffrey E. ; Xiao, Lianchun ; Pisters, Peter W. T. ; Vauthey, Jean-Nicolas ; Abdalla, Eddie K. ; Wolff, Robert A. ; Varadhachary, Gauri R. ; Fogelman, David R. ; Crane, Christopher H. ; Balachandran, Aparna ; Katz, Matthew H. G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-9d33414a909f00e27e232760bbf02d4d404803bf73ccd914366651609b738fc83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - therapy</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carcinoma, Pancreatic Ductal - mortality</topic><topic>Carcinoma, Pancreatic Ductal - pathology</topic><topic>Carcinoma, Pancreatic Ductal - therapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Combined Modality Therapy</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gemcitabine</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoadjuvant Therapy - mortality</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Pancreatectomy - mortality</topic><topic>Pancreatic Neoplasms - mortality</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Pancreatic Neoplasms - therapy</topic><topic>Pancreatic Tumors</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tzeng, Ching-Wei D.</creatorcontrib><creatorcontrib>Fleming, Jason B.</creatorcontrib><creatorcontrib>Lee, Jeffrey E.</creatorcontrib><creatorcontrib>Xiao, Lianchun</creatorcontrib><creatorcontrib>Pisters, Peter W. T.</creatorcontrib><creatorcontrib>Vauthey, Jean-Nicolas</creatorcontrib><creatorcontrib>Abdalla, Eddie K.</creatorcontrib><creatorcontrib>Wolff, Robert A.</creatorcontrib><creatorcontrib>Varadhachary, Gauri R.</creatorcontrib><creatorcontrib>Fogelman, David R.</creatorcontrib><creatorcontrib>Crane, Christopher H.</creatorcontrib><creatorcontrib>Balachandran, Aparna</creatorcontrib><creatorcontrib>Katz, Matthew H. G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tzeng, Ching-Wei D.</au><au>Fleming, Jason B.</au><au>Lee, Jeffrey E.</au><au>Xiao, Lianchun</au><au>Pisters, Peter W. T.</au><au>Vauthey, Jean-Nicolas</au><au>Abdalla, Eddie K.</au><au>Wolff, Robert A.</au><au>Varadhachary, Gauri R.</au><au>Fogelman, David R.</au><au>Crane, Christopher H.</au><au>Balachandran, Aparna</au><au>Katz, Matthew H. G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy</atitle><jtitle>Annals of surgical oncology</jtitle><stitle>Ann Surg Oncol</stitle><addtitle>Ann Surg Oncol</addtitle><date>2012-06-01</date><risdate>2012</risdate><volume>19</volume><issue>6</issue><spage>2045</spage><epage>2053</epage><pages>2045-2053</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>Background
We previously introduced a classification system for patients with localized pancreatic adenocarcinoma that integrates assessments of tumor anatomy, cancer biology, and patient physiology. By means of this system, we sought to analyze outcomes of patients with resectable anatomy but heterogeneous biology and physiology who were treated with neoadjuvant therapy.
Methods
We evaluated consecutive patients (2002–2007) with anatomically potentially resectable cancers treated with chemotherapy or chemoradiation before potential pancreatectomy. We compared clinical factors and outcomes of patients classified as having disease that was clinically resectable (CR; no extrapancreatic disease, preserved performance status); suspicion for extrapancreatic disease (BR-B); or marginal performance status or significant comorbidity (BR-C). Patients with borderline resectable anatomy (BR-A) were excluded.
Results
Resection rates for 138 CR, 41 BR-B, and 38 BR-C patients were 75, 46, and 37%, respectively (
P
< 0.001). Metastases, detected during treatment in 23% of patients, were the most common contraindication to resection among CR (15%) and BR-B (46%) patients. Performance status rarely precluded surgery except among BR-C (32%) patients. Factors associated with selection against surgery were older age, poor performance status, pain, and therapeutic complications (
P
< 0.05). The median overall survival of all patients was 21 months. Resected and unresected BR-B and BR-C patients had median overall survival durations similar to those of resected and unresected CR patients, respectively (
P
> 0.22).
Conclusions
This system describes discrete clinical subgroups of patients with pancreatic cancer who have similar, potentially resectable tumor anatomy but heterogeneous physiology and cancer biology. It may be used with neoadjuvant therapy to predict outcomes, individualize treatment algorithms, and optimize survival.</abstract><cop>New York</cop><pub>Springer-Verlag</pub><pmid>22258816</pmid><doi>10.1245/s10434-011-2211-4</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1068-9265 |
| ispartof | Annals of surgical oncology, 2012-06, Vol.19 (6), p.2045-2053 |
| issn | 1068-9265 1534-4681 |
| language | eng |
| recordid | cdi_proquest_journals_1015012084 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adenocarcinoma - mortality Adenocarcinoma - pathology Adenocarcinoma - therapy Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Pancreatic Ductal - mortality Carcinoma, Pancreatic Ductal - pathology Carcinoma, Pancreatic Ductal - therapy Cisplatin - administration & dosage Combined Modality Therapy Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Female Follow-Up Studies Gemcitabine Humans Male Medicine Medicine & Public Health Neoadjuvant Therapy - mortality Neoplasm Staging Oncology Pancreatectomy - mortality Pancreatic Neoplasms - mortality Pancreatic Neoplasms - pathology Pancreatic Neoplasms - therapy Pancreatic Tumors Prognosis Retrospective Studies Surgery Surgical Oncology Survival Rate |
| title | Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T10%3A21%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Defined%20Clinical%20Classifications%20Are%20Associated%20with%20Outcome%20of%20Patients%20with%20Anatomically%20Resectable%20Pancreatic%20Adenocarcinoma%20Treated%20with%20Neoadjuvant%20Therapy&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Tzeng,%20Ching-Wei%20D.&rft.date=2012-06-01&rft.volume=19&rft.issue=6&rft.spage=2045&rft.epage=2053&rft.pages=2045-2053&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1245/s10434-011-2211-4&rft_dat=%3Cproquest_cross%3E2666003591%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1015012084&rft_id=info:pmid/22258816&rfr_iscdi=true |